Do you want to read an article? Please log in or register.
Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-related Macular Degeneration: A Phase 3 Randomized Trial
Macular Diseases
Related content
Macular Diseases
Efficacy and safety of brolucizumab every 6 weeks induction therapy for neovascular age-related macular degeneration
Sci Rep
Honda S, Maruyama-Inoue M, Otsuji T, Kyo A, Kobayashi Y, Yamamoto Y, Gomi F
doi: 10.1038/s41598-025-89638-1
Macular Diseases
Tissue Plasminogen Activator or Perfluoropropane for Submacular Hemorrhage in Age-Related Macular Degeneration: A Factorial Randomized Clinical Trial
JAMA Ophthalmol
Murphy GSP, Saleh A, Ayis S, Cheema MR, Mehta A, Steel DH, Membrey L, Costen M, Jackson TL
doi: 10.1001/jamaophthalmol.2024.4297
Macular Diseases
Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice
Ophthalmol Ther
Debourdeau E, Beylerian H, Nguyen V, Barthelmes D, Gillies M, Gabrielle PH, Vujosevic S, Otoole L, Puzo M, Creuzot-Garcher C, Wolff B, Daien V, Fight Retinal Blindness! Study Group
doi: 10.1007/s40123-024-00983-2
RECOMMENDED
Macular DiseasesFurther Publications
Cocoa Flavanol Supplementation and Risk of Age-Related Macular Degeneration: An Ancillary Study of the COSMOS Randomized Clinical Trial
★ 1
Recommended by
Prof. emer. Dr Josef Flammer, Faculty Member
JAMA Ophthalmol
Christen WG, Rist PM, Moorthy MV, Smith DC, Holman B, Clar A, Glynn RJ, Mares JA, Sobrin L, Shadyab AH, Allison MA, Millen AE, Manson JE, Sesso HD, COSMOS Research Group
doi: 10.1001/jamaophthalmol.2025.0353
Macular Diseases
TALON Phase IIIb Study: 32 Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age Related Macular Degeneration
Ophthalmol Retina
Regillo C, Kaiser PK, Kertes PJ, Gillies M, Maio-Twofoot T, D'Souza D, Guenther S, Lawrence D, Holz FG
doi: 10.1016/j.oret.2025.05.030
Macular Diseases
Omega-3 Fatty Acids as Protective Factors for Age-related Macular Degeneration: Prospective Cohort and Mendelian Randomization Analyses
Ophthalmology
Xue CC, Li H, Yu M, Chong CCY, Fan Q, Tham YC, Cheung CMG, Wong TY, Chew EY, Cheng CY
doi: 10.1016/j.ophtha.2024.12.005
RECOMMENDED
Macular Diseases
Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis
★ 3
Recommended by
Prof. emer. Dr Josef Flammer, Faculty Member
Ophthalmol Retina
Berni A, Coletto A, Li J, Shen M, Bandello F, Reibaldi M, Borrelli E
doi: 10.1016/j.oret.2025.01.011
Macular Diseases
Comparative efficacy of intravitreal anti-VEGF therapy for neovascular age-related macular degeneration: A systematic review with network meta-analysis
Acta Ophthalmol
Butler ETS, Arnold-Vangsted A, Schou MG, Anguita R, Bjerager J, Borrelli E, Cehofski LJ, Ferro Desideri L, van Dijk EHC, Faber C, Grauslund J, Hajari JN, Huemer J, Klefter ON, Krogh Nielsen M, Sabaner MC, Schneider M, Subhi Y
doi: 10.1111/aos.17506
Macular DiseasesRetinal Diseases
Fight Retinal Blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study
Eye (Lond)
Puzo M, Calvo-Perez P, Bartol-Puyal F, Sanchez-Monroy J, Martin-Pinardel R, Parrado-Carrillo A, Moll-Udina A, Bernal-Morales C, Sanchez-Vela L, Sararols-Ramsay L, Garay-Aramburu G, Arruabarrena C, García-Arumí J, Abraldes M, Ruiz-Moreno JM, Valldeperas X, Velázquez-Villoria D, Escobar-Barranco JJ, Gallego-Pinazo R, Figueroa MS, Figueras-Roca M, Barthelmes D, Gillies MC, Casaroli-Marano RP, Zarranz-Ventura J, from the writing committee of the Fight Retinal Blindness Spain (FRB! Spain) Users Group
doi: 10.1038/s41433-024-03322-8